Provides actionable preclinical evidence for repurposing the PPARγ agonist pioglitazone as a schedule-dependent, potentially disease-modifying therapy for PD by linking a specific dosing regimen to aggregate reduction and neuroprotection, justifying further mechanistic and translational studies.

Provides a mechanistically actionable lead—ferroptosis modulation by a marine-derived microbe—with biomarker readouts and clear neuroprotective effects in vivo, offering a promising source of bioactive compounds for PD drug discovery that warrants validation in mammalian models.

By demonstrating mitochondrial and anti-apoptotic effects tied to a defined compound (glabridin), the work points to a tractable antioxidant lead with mechanistic relevance to Parkinson's-related oxidative stress that warrants isolation, target validation, and in vivo testing.

Provides a potentially translatable neuroprotective approach combining intranasal nanoparticle delivery and plant-derived phenolics that reduces neuroinflammation and dopaminergic loss in a PD model, meriting further mechanistic, pharmacokinetic, and alpha-synuclein–relevant validation.

Identifies actionable molecular pathways linking exercise to neuroprotection—useful for designing nonpharmacologic interventions, biomarker-driven trials, or adjunctive therapeutic strategies—while flagging translational gaps due to limited human data and homogeneous exercise models.

HTRA1 influences proteostasis, inflammation, and vascular/ECM integrity—mechanisms relevant to Parkinson’s pathobiology and drug targeting—so the review highlights a moderately actionable target space (including inhibitors and biomarkers), but it lacks direct, PD-specific links to core processes…

The study has moderate translational value because it informs clinical trial endpoint selection and patient stratification by showing that dopaminergic therapy can reshape motor phenotype, but it offers limited mechanistic targets or direct therapeutic leads for drug discovery.

Clinically relevant, immediately actionable combination therapy using repurposed agents suggests a potential strategy to reduce levodopa exposure and limit dyskinesia, but the nonrandomized retrospective design means randomized controlled trials are required to validate efficacy and safety.

By synthesizing scaffold engineering, vascularization, immune compatibility, and GMP manufacturing challenges, the paper highlights practical strategies that could improve stem-cell survival, integration, and translational readiness for Parkinson’s cell-replacement and disease-modeling applications.

Clinically useful for improving identification and symptomatic management of depression in PD and for informing research on affective circuitry and neuromodulation, but offers limited direct insight into molecular disease-modifying targets for Parkinson's therapeutic discovery.

By linking GPX4 dysfunction to iron-dependent lipid peroxidation and cataloguing modulators, the paper highlights a tractable ferroptosis axis (oxidative/iron biology and glutathione metabolism) that could be exploited for Parkinson's drug discovery and repurposing efforts.

By consolidating mechanistic hypotheses and treatment approaches—especially iron-related pathways and dopaminergic therapies—the paper highlights actionable targets and clinical strategies that could be pursued in translational studies to improve sleep and quality of life in PD patients.

It highlights the gut-brain axis as a translationally relevant target and compiles potential microbiome-based interventions that can be prioritized for preclinical validation and clinical trials in PD.

Provides causal, cell-type–specific evidence that indirect-pathway D2 receptors and their downstream GPe PV neuron activation drive L-DOPA-induced dyskinesia, pointing to targeted circuit- or cell-specific interventions (gene therapy, circuit modulators, or downstream signaling blockers) to reduce…

Provides a translationally relevant strategy to overcome blood–brain barrier delivery hurdles for Parkinson's therapeutics—potentially enabling more effective brain delivery of existing or new drugs even though it does not propose specific PD-targeted mechanisms or candidate therapeutics.

The review highlights multiple mechanisms (mitochondrial protection, anti-inflammatory effects, aggregation inhibition) that are directly relevant to Parkinson's therapeutic targets and provides a useful source of peptide leads for follow-up PD-focused validation and optimization despite…

Highlights actionable mechanistic pathways (epigenetics, neuroinflammation, mitochondrial dysfunction) that can guide biomarker development and early-intervention or prevention studies, though it offers limited direct, short-term therapeutic candidates.

Useful for therapeutic discovery because it consolidates multiple actionable target areas (inflammation, alpha‑synuclein, cholinergic and synaptic mechanisms, gut–brain interactions) to guide prioritization and repurposing, though its narrative review format and lack of novel data limit immediate…

By synthesizing mechanisms like BBB disruption, neurovascular uncoupling, inflammation and therapeutic approaches (lifestyle, glucose-lowering, vasoprotective strategies), the paper highlights indirectly actionable vascular and metabolic targets that could be explored to modulate vascular…

Shows a clinically actionable, sex-specific levodopa-sparing effect for an approved MAO-B inhibitor that could guide personalized adjunctive therapy to reduce dyskinesia risk and should be tested prospectively.

Highlights non-dopaminergic contributors and potential repurposable targets for PD-related apathy/anhedonia, supporting biomarker-driven patient stratification and development of targeted symptomatic therapies when dopaminergic treatment is insufficient.

By directly targeting alpha-synuclein aggregation while also mitigating oxidative/ER stress and inflammation, IP-045 represents a translationally promising multi-target lead for disease-modifying PD therapies, although further pharmacokinetic, safety, and mechanistic validation is required.

Defines a druggable TMBIM6–IRE1α axis with mechanistic, human tissue, pharmacologic, and gene‑therapy evidence, providing a translational target and potential biomarker pathway for neuroprotective therapies in Parkinson’s disease.

Because valsartan is an approved, brain‑penetrant drug showing multimodal, disease‑modifying signals (Nurr1 activation, epigenetic modulation, α‑syn reduction) that support repurposing for PD, though findings need replication in toxin/genetic neurodegeneration models and translational studies.

By providing in vitro and in vivo evidence that a small natural compound can pharmacologically restore mitochondrial biogenesis and function via a defined SIRT1/PGC-1α pathway, the study offers an actionable therapeutic lead and biomarker axis for PD drug discovery, while translation will require…